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Multifunctional roles of the autoimmune disease-associated tyrosine
phosphatase PTPN22 in regulating T cell homeostasis
Robert J Salmond, Rebecca J Brownlie, and Rose Zamoyska*
Institute of Immunology and Infection Research; Ashworth Laboratories; University of Edinburgh; Edinburgh, UK
The non-receptor tyrosine phospha-tase PTPN22 has a vital function in
inhibiting antigen-receptor signaling in
T cells, while polymorphisms in the
PTPN22 gene are important risk alleles
in human autoimmune diseases. We
recently reported that a key physiological
function of PTPN22 was to prevent
na€ıve T cell activation and effector cell
responses in response to low affinity anti-
gens. PTPN22 also has a more general
role in limiting T cell receptor-induced
proliferation. Here we present new data
emphasizing this dual function for
PTPN22 in T cells. Furthermore, we
show that T cell activation modulates the
expression of PTPN22 and additional
inhibitory phosphatases. We discuss the
implication of these findings for our
understanding of the roles of PTPN22 in
regulating T cell responses and in
autoimmunity.
Introduction
A critical feature of adaptive immunity
is the ability of T cells to discriminate
between benign environmental or self-anti-
gens (Ag) and dangerous infectious agents.
In order to accomplish this task, the pro-
cesses of positive and negative selection in
the thymus ensure central tolerance i.e.,
the development of a diverse peripheral T
cell repertoire that expresses functional T
cell receptors (TCRs) capable of recogniz-
ing foreign Ag while having low affinity for
self Ag (reviewed in 1). Furthermore,
peripheral tolerance mechanisms are also
critical to prevent inappropriate activation
of T cells and subsequent inflammation
and autoimmunity. Such mechanisms
include the specialized suppressive
functions of FoxP3C regulatory T cells
(Tregs)2 and, in addition, effector T cell-
intrinsic processes. The expression and
function of inhibitory protein tyrosine
phosphatases in TCR signaling pathways is
one such cell-intrinsic mechanism by
which effector T cell activation is limited.3
T cell receptor engagement by peptide-
MHC complexes induces the phosphory-
lation of immunoreceptor tyrosine-based
activation motifs within the intracellular
tails of the TCR / CD3 complex by the
src-family kinase Lck.4 This in turn leads
to recruitment and activation of the Syk
family kinase zeta chain-associated protein
kinase of 70 kDa (ZAP70) and the initia-
tion of a signaling cascade that ultimately
results in the activation of gene expression,
metabolic reprogramming, cell growth
and division and the acquisition of special-
ized effector cell functions such as cyto-
kine secretion and target cell cytotoxicity
(reviewed in 5). Importantly, inhibitory
tyrosine phosphatases, such as PTPN22,
are critical both in setting the threshold
for initial T cell activation and in facilitat-
ing the return of the cells to a resting state
by downregulating the activation of these
signaling pathways. Of particular interest
we, and others, generated mice deficient
in expression of PTPN22 and showed that
this cytoplasmic tyrosine phosphatase is
critical for maintaining T cell homeosta-
sis.6,7 Furthermore, a wealth of data has
accumulated in the past decade identifying
PTPN22 single-nucleotide polymor-
phisms (SNPs) as risk factors for the
development of autoimmune diseases
such as rheumatoid arthritis, type 1 diabe-
tes and lupus (reviewed in 8).
Recently, we reported that PTPN22
function is important for the ability of
T cells to discriminate between low
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affinity self-Ag and high affinity foreign
Ag.9 In this Extra Views article, we dis-
cuss the mechanisms by which PTPN22
regulates TCR activation in response to
low affinity Ag, yet also has a more
general role in limiting T cell prolifera-
tion in vivo. Furthermore, we discuss
how T cells regulate phosphatase
expression, the overlapping and non-
redundant functions of PTPN22 and
other inhibitory phosphatases in T cell
activation and the implications of our
results for our understanding of the role
of PTPN22 in autoimmunity.
Materials and Methods
Mice and cell transfer experiments
Ptpn22 exon 1fl/fl £ PC3-Cre, Ptpn22
exon 1fl/fl £ PC3-Cre OT-1 Rag1¡¡ and
Ptpn22 exon 1fl/fl £ dLck-Cre mice strains
have been described.6,9 Rag1¡¡,
CD45.1C, CD45.2C and OT-1 CD45.1C
mice were bred in-house at the University
of Edinburgh. For transfer experiments,
bone marrow-derived dendritic cells were
generated in the presence of GM-CSF, as
previously described.10 3 £ 104 WT and
Ptpn22¡¡ OT-1 T cells were co-trans-
ferred with peptide-loaded or control den-
dritic cells to CD45.1/CD45.2 recipient
mice. In some experiments, 2.5-5 £ 105
sorted WT and Ptpn22¡¡ na€ıve CD44low
CD4C T cells were transferred i.v. to suble-
thally irradiated recipient mice. Where
indicated, mice received i.p. injections of
300 mg IL-7R mAb (clone A7R34) every
48 h over the course of the experiment. In
some experiments, recipient mice received
ampicillin, metronidazole, neomycin sul-
fate and vancomycin (1 g/L) in drinking
water for 10 d preceding cell transfer and
throughout the course of the experiment.
Flow cytometry analysis of lymph node T
cells was performed using a MACSQuant
flow cytometer (Miltenyi Biotech). Anti-
bodies were from BD PharMingen, eBio-
science and BioLegend. All animal
procedures were licensed by the UK Home
Office and performed in line with the ethi-
cal guidelines of the University of
Edinburgh.
Quantitative RT-PCR and western
blotting
For RT-PCR, WT OT-1 cells were
stimulated for the stated time periods with
10¡8 M SIINFEKL (N4) peptide and
total RNA prepared using Qiagen
RNEasy columns. cDNA was synthesized
using Superscript reverse transcriptase and
quantitative PCR performed using Taq-
man probes (both Life Technologies).
Levels of mRNA expression of phospha-
tase genes Ptpn22, Ptpn6, Ptpn11, Dusp5
and Dusp6 were normalized to expression
of rn18s. For protein gel blotting, na€ıve
CD44low and effector-memory phenotype
CD44high CD8C T cells were sorted by
flow cytometry from lymph nodes of
C57BL/6J mice and cell lysates prepared
in RIPA lysis buffer. Western blots were
performed using ERK2 rabbit polyclonal
Abs (Santa Cruz Biotechnology) and the
PTPN22 P1 Ab (a kind gift of Prof. A.
Chan, Genentech).
Results and Discussion
Mouse models of PTPN22 function
in T cell homeostasis
In order to determine the role of
PTPN22 in T cell activation, we gener-
ated mice with homozygous expression of
Ptpn22 alleles with floxed exon 1.6 Mice
were crossed with the PC3-Cre transgenic
or distal (d)Lck-Cre transgenic strains in
order to generate mice with ubiquitous
(Ptpn22¡¡) or T cell-specific deletion of
Ptpn22 (Ptpn22fl/fl dLck), respectively. Of
note, dLck-Cre drives deletion of floxed
genomic sequences in post-selection thy-
mocytes thus negating possible effects of
gene deletion on thymocyte selection pro-
cesses.11 In the complete absence of
PTPN22, mice develop splenomegaly and
lymphadenopathy as a consequence of
increased numbers and frequencies of
effector and effector-memory phenotype
T cells and present with elevated antibody
titres and increased numbers of germinal
centers.6,7,12 Treg function and number is
also elevated and is likely to be necessary
to curb the highly inflammatory effector
T cells present in Ptpn22-deficient mice,
thereby preventing the induction of spon-
taneous autoimmunity.6,13 The nature of
the defect in T cell homeostasis that
occurs in the absence of PTPN22 was
investigated by crossing PTPN22-defi-
cient mice to an OT-1 TCR transgenic
background. OT-1 T cells express an
MHC Class-I restricted TCR specific for
the SIINFEKL peptide derived from oval-
bumin.14 Altered peptide ligands of SIIN-
FEKL were used to determine the impact
of PTPN22 loss on responses to Ag of
varying affinities.
Lymphopenia promotes autoreactivity
that is counteracted by PTPN22
One situation, in which otherwise toler-
ant T cells can be driven to proliferate and
gain effector function in response to self-
Ag, is transient or chronic lymphopenia.
Elevated levels of stromal-derived homeo-
static cytokines such as IL-7 and IL-15
combine with TCR-dependent responses
to low affinity and environmental Ags to
drive lymphopenia-induced proliferation
(LIP).15 Interestingly, recent evidence has
shown that LIP is a primary cause of sec-
ondary autoimmunity in cohorts of multi-
ple sclerosis (MS) patients. Thus, patients
treated with alemtuzumab to deplete
autoreactive lymphocytes showed relief
from MS symptoms; however, a propor-
tion of the patients suffered secondary
autoimmune thyroiditis as a consequence
of T cell population expansion in the lym-
phopenic environment.16
We showed that PTPN22 is important
to limit LIP as both Ptpn22¡¡ CD8C
OT-1 TCR transgenic and polyclonal
na€ıve Ptpn22¡¡ CD4C T cell populations
expanded to a greater extent than their
WT counterparts upon co-transfer to lym-
phopenic Rag1¡¡ or sublethally irradiated
recipient mice.9 To determine whether
this was a consequence of increased
responsiveness to cytokines and/or weak
TCR agonists, we performed several addi-
tional experiments. Congenically marked
na€ıve polyclonal CD4C T cells from WT
CD45.1C and Ptpn22¡¡ CD45.2C mice
were purified by FACS-sorting and co-
transferred to sublethally irradiated
CD45.1/CD45.2 mice that were subse-
quently treated with either a blocking IL-
7R mAb or diluent. While IL-7R block-
ade reduced both WT and Ptpn22¡¡ LIP
(data not shown), the relative increase in
the ratio of Ptpn22¡¡ WT cells seen in
untreated mice was exacerbated by IL-7R
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mAb treatment (Fig. 1A). Similar results
were seen with CD8C OT-1 TCR trans-
genic T cells9 indicating that PTPN22 is
required to restrain both CD4C and
CD8C T cell responses to TCR signals in
lymphopenic conditions.
In irradiated and immunodeficient
mice, polyclonal T cells populations can
be driven to expand by antigens derived
from enteric bacteria due to a breakdown
in gut integrity.17 In order to limit such
responses, purified na€ıve CD4C T cells
from WT CD45.1C, Ptpn22¡¡ CD45.2C
and Ptpn22fl/fl dLck GFPC mice were
mixed 1:1:1 and co-transferred into suble-
thally irradiated host mice that were
treated with an antibiotic cocktail. In anti-
biotic-treated recipient mice, CD4C T
cells from both Ptpn22¡¡ and Ptpn22fl/fl
dLck mice expanded to a significantly
greater extent than WT cells (Fig. 1B).
Importantly, there was no significant dif-
ference in the response of Ptpn22¡¡ and
Ptpn22fl/fl dLck cells. As Ptpn22fl/fl dLck
cells lose expression of PTPN22 protein
after positive selection, these data confirm
that the increased responsiveness of
Ptpn22 knockout T cells is not likely to be
the result of altered selection in the thy-
mus. Taken together, these experiments
suggest that the enhanced LIP of
PTPN22-deficient T cells is driven pri-
marily by self- rather than microbial Ags.
Further experiments confirmed that
PTPN22-deficiency had a striking impact
on the responses of OT-1 T cells to low
affinity Ag. Thus, activation of TCR sig-
naling pathways and induction of expres-
sion of key transcription factors and
cytokines by weak agonists was markedly
enhanced in the absence of PTPN22,
whereas most initial responses to high
affinity SIINFEKL peptide were indistin-
guishable from those of WT cells.9
Together, these data suggest that a pri-
mary function of PTPN22 in T cells is to
prevent inappropriate activation of T cells
by low affinity and self-Ag. This raises the
important questions: are disease-associated
PTPN22 variants functionally impaired in
the regulation of LIP and responses to
self-Ag and does this underly the role of
these polymorphisms in autoimmune
disease?
The disease-associated PTPN22
1858C!T SNP, that results in an
R620W amino acid substitution, was ini-
tially described to result in a gain of func-
tion variant protein with higher catalytic
activity,18,19 while others have argued that
the polymorphism results in a loss of
PTPN22 function.20 More recently, sev-
eral groups have demonstrated that
Ptpn22 R619W knock-in mice, modeling
WT KO WT KO WT KO
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Figure 1. Elevated LIP of Ptpn22¡/- T cells is driven by low afﬁnity TCR signals. (A) IL-7R blockade
exaggerates the increase in the KO:WT T cell ratio in lymphopenic hosts. Polyclonal WT and
Ptpn22‑/¡ na€ıve CD4C T cells were mixed»1:1 (injection (inj) mix) and transferred to sublethally irra-
diated recipient mice. Groups of mice received i.p. injections of IL-7R mAb (C IL-7R) every second
day. (B) Antibiotic treatment does not prevent enhanced LIP of PTPN22-deﬁcient T cells. Na€ıve
CD4C T cells from WT, Ptpn22--/¡ (KO) and Ptpn22ﬂ/ﬂ dLck mice were mixed »1:1:1 (Inj. Mix) and
transferred to sublethally irradiated, antibiotic treated mice. In all cases after 14d, proportions of
donor T cells in LN were assessed by ﬂow cytometry. Lines represent mean values within groups
and circles represent values from individual mice. ns – not signiﬁcant, * - P < 0.05, ** - P < 0.01,
*** - P < 0.001 by paired Students’ t-test.
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the human SNP, have a similar, albeit
milder, immunological phenotype as
Ptpn22-deficient mice.21,22 Irrespective of
the precise molecular consequences of the
disease-associated SNPS on PTPN22
function, it may prove insightful to inves-
tigate the impact of R619W/R620W var-
iants on LIP. For example, while PTPN22
SNPs are not associated with susceptibility
to MS, it would be of great interest to
assess whether expression of these alleles
influences the risks of secondary autoim-
munity following alemtuzumab
treatment.16
PTPN22 regulates T cell proliferation
While our data indicate that PTPN22
is critical for regulating early TCR signals
that facilitate discrimination of low affin-
ity Ag, PTPN22 also plays a more general
role in later aspects of the response, partic-
ularly in the control of TCR-induced pro-
liferation. Previous data from our
laboratory and others demonstrated that,
upon stimulation with CD3/CD28 anti-
bodies, Ptpn22¡/¡ T cells proliferated to a
greater extent than WT counterparts in
vitro.6,7 Furthermore, we reported
enhanced population expansion of
Ptpn22¡/¡ OT-1 T cells in response to
SIINFEKL peptide in vitro or after trans-
fer of the T cells into Rag1¡/¡ mice and
infection with ovalbumin-expressing Liste-
ria monocytogenes (LmOva) bacteria.9 The
lymphopenic environment of the Rag1¡¡
recipient mice complicates the interpreta-
tion of the results from LmOva infection
experiments. Therefore, to address how
Ptpn22¡/¡ OT-1 T cells behave in a T cell
replete environment, WT CD45.1/
CD45.2 OT-1 and Ptpn22¡/¡ CD45.2
OT-1 T cells were mixed 1:1 and trans-
ferred to lymphocyte replete CD45.1
hosts. Recipient mice were then chal-
lenged with ovalbumin-loaded bone mar-
row-derived dendritic cells (Ova-DCs) or
control DCs. Seven days after challenge,
lymph nodes were taken from mice and
the proportions of donor OT-1 T cells
evaluated by flow cytometry (Fig. 2A).
Both WT and Ptpn22¡/¡ OT-1 cells pro-
liferated in response to Ova-DCs, as evi-
dent by the enhanced proportions of these
cells present in LNs as compared to con-
trol DC-treated mice (Fig. 2B). Similar to
results in lymphopenic Rag1¡/¡
environments, Ptpn22¡/¡ OT-1 T cells
were proportionally increased in compari-
son to WT cells in all Ova-DC recipient
mice, confirming that expression of
PTPN22 limits the proliferation of WT T
cells to high affinity cognate Ag in vivo
(Fig. 2B).
These data confirm that PTPN22
expression regulates the expansion of T
cells to both strong and weak antigens,
Figure 2. Increased expansion of Ptpn22‑/¡ T cell populations in response to in vivo challenge with
high afﬁnity antigen. CD45.1/CD45.2 WT and CD45.2 Ptpn22‑/¡ OT-1 T cells were transferred i.v. to
CD45.1 recipient mice that were subsequently challenged i.v. with unpulsed (control) or ovalbu-
min-pulsed (Ova) DCs. After 7d, proportions of host and donor CD8C T cells in LNs were assessed
by ﬂow cytometry (A). Lines represent mean values within groups and circles represent values from
individual mice (B).
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raising the question: how does PTPN22
limit T cell proliferation? In this regard,
levels of the key transcription factor cMyc
were elevated in Ptpn22¡¡ as compared
to WT OT-1 T cells following 24 h stim-
ulation with strong agonist SIINFEKL
peptide as well as in responses to weaker
agonists.9 Importantly, cMyc has an essen-
tial role in the regulation of cell cycle pro-
gression and for the metabolic changes
required for proliferation and differentia-
tion of T cells following TCR trigger-
ing.23 A further, not mutually exclusive,
possibility is that enhanced autocrine pro-
duction of IL-2, as has been shown for
Ptpn22¡¡ polyclonal CD4C T cells,7
drives the elevated levels of proliferation.
Activation-induced regulation of
phosphatase expression in T cells
Recent evidence has shown that T
cells modulate the level of expression of
inhibitory phosphatases in response to
TCR triggering. For example, PTPN6
(SHP-1) expression is upregulated upon
T cell stimulation and may act to coun-
teract responses to high affinity Ags.24
We performed quantitative RT-PCR
experiments to assess the levels of
expression of PTPN22 and additional
inhibitory phosphatases at various time-
points after OT-1 T cell activation.
Levels of PTPN22, PTPN6, PTPN11,
DUSP5 and DUSP6 mRNA were low
in na€ıve OT-1 T cells and strongly
upregulated following 24 h of stimula-
tion with agonist SIINFEKL peptide
(Fig. 3A–E). With the exception of
PTPN22 and PTPN6, however, mRNA
for the other phosphatases examined
tended to decline by 48 h, by which
time the T cells have entered division.
We confirmed by western blotting that
high levels of PTPN22 were maintained
in effector/memory phenotype T cells
by comparing PTPN22 abundance in
naturally arising CD44high T cells ex
vivo with na€ıve T cells (Fig. 3F).
The expression of several tyrosine
phosphatases and dual-specificity phos-
phatases is also downregulated in T cells
in a coordinated manner via the action of
micro-RNAs (miR). Specifically, miR-
181a acts to enhance TCR signaling by
downregulating expression of PTPN22,
PTPN11, DUSP5 and DUSP6, but not
PTPN6.25 Interestingly miR-181a is
expressed at higher levels in na€ıve T cells,
relative to effector Th1 or Th2 popula-
tions,25 consistent with the low level
expression of its target phosphatases in
na€ıve T cells. Together, these data imply
that low level expression of PTPN22 (and
possibly other phosphatases) is sufficient
to limit na€ıve T cell activation by low
affinity and self-Ags but does not curb
Figure 3. Activation-induced upregulation of phosphatase expression in OT-1 T cells. (A-E) Levels of individual phosphatase mRNAs in WT OT-1 cells
stimulated with SIINFEKL (N4) peptide in vitro for 0–48 h were calculated by qRT-PCR. Values are normalized to expression of 18S rRNA and represent
means § SEM (n D 3). (F) Western blot analysis of PTPN22 expression in FACS-sorted na€ıve and effector-memory (Eff/Mem) phenotype polyclonal CD8C
T cells. ERK2 serves as a loading control. Data are representative of 2 repeated experiments.
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responses to high-affinity foreign Ag. By
contrast, the upregulation of PTPN22
and other inhibitory phosphatases upon
TCR triggering likely acts as a safeguard
to prevent excessive T cell-mediated
inflammation following activation.
Overlapping functions of tyrosine
phosphatases in T cells?
Our recent data indicates that PTPN22
has a non-redundant function in control-
ling responses of na€ıve T cells in a lym-
phopenic environment and in response to
low affinity Ag.9 Despite this, it is impor-
tant to note that other phosphatases also
function to limit LIP. T cells deficient in
expression of PTPN2 (T cell-PTP) also
undergo rapid proliferation upon transfer
to lymphopenic hosts.26 Furthermore,
similar to the effects of PTPN22-defi-
ciency, the elevated LIP of Ptpn2¡¡ T
cells is a result of elevated TCR-driven,
rather than IL-7-driven, responsiveness. It
is interesting to note that the expression of
polymorphisms in PTPN2 have also been
associated with an enhanced risk of devel-
oping autoimmunity.27,28
It is possible that the similarity of phe-
notypes of Ptpn2¡¡ and Ptpn22¡¡ T cells
results from shared substrate specificity.
The regulation of phosphorylation of
upstream kinases such as Lck is important
for the promotion and termination of
TCR signaling. Several phosphatases
including PTPN22, PTPN2, PTPN6 and
CD45 negatively regulate Lck function by
modulating levels of phosphorylation of
the active site Tyr394 residue.29-33 In each
case, whether these effects are via direct
dephosphorylation or are indirect has yet
to be fully elucidated. Nonetheless, it is
clear that several phosphatases are
expressed in T cells that have shared func-
tionality. The apparently counter-intuitive
observations that PTPN2 and PTPN22
have similar targets in TCR signaling yet
are not functionally redundant may be
explained by their distinct patterns of
expression. Thus, PTPN22 is expressed at
low levels in na€ıve T cells (Fig. 3) whereas
PTPN2 is expressed at elevated levels in
this population and while PTPN22
expression increases upon activation the
abundance of PTPN2 protein remains
constant.26 Alternatively, it may be that
there are simply insufficient quantities of
either phosphatase alone to accomplish
efficient regulation of TCR proximal
signaling.
Conclusions
Our recent data have provided insight
into the physiological functions of
PTPN22 in the regulation of T cell toler-
ance. Future work may unravel how these
mechanisms are perturbed by SNPs and
aid in our understanding of the molecular
basis of T cell-mediated autoimmune
disease.
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